Martine J. Piccart
#144,961
Most Influential Person Across History
Martine J. Piccart's AcademicInfluence.com Rankings
Download Badge
Medical Philosophy
Martine J. Piccart's Degrees
- Doctorate Medicine Université libre de Bruxelles
- PhD Oncology Université libre de Bruxelles
Why Is Martine J. Piccart Influential?
(Suggest an Edit or Addition)Martine J. Piccart's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. (2012) (2045)
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. (2006) (1930)
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. (2013) (1281)
- Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) (1199)
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. (2016) (1176)
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. (2012) (1142)
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
- Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) (1032)
- Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. (2000) (1001)
- Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures (2007) (868)
- Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer (2017) (847)
- Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. (2007) (814)
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes (2008) (794)
- CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013) (712)
- 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015) (627)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (2009) (588)
- A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. (2003) (570)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? (2007) (473)
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
- ESMO-Magnitude of Clinical Benefit Scale version 1.1 (2017) (396)
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
- Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. (2000) (391)
- Clinical management of breast cancer heterogeneity (2015) (382)
- Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen (2008) (368)
- Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. (2000) (352)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) (345)
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer (2010) (340)
- Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. (2002) (334)
- Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours (2005) (329)
- An update on PARP inhibitors—moving to the adjuvant setting (2015) (320)
- Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? (2005) (315)
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling (2012) (308)
- Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. (2008) (299)
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
- HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. (2002) (290)
- Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. (2014) (262)
- Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (2008) (261)
- Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. (1994) (260)
- Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial (2006) (253)
- Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (2000) (243)
- Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials (2012) (239)
- Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. (2013) (228)
- Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. (2003) (227)
- Long-term toxic effects of adjuvant chemotherapy in breast cancer. (2011) (226)
- Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. (2014) (221)
- Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. (2003) (221)
- Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer (2011) (217)
- Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. (2002) (216)
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. (2016) (212)
- 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. (2016) (205)
- Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. (2012) (205)
- DNA methylation profiling reveals a predominant immune component in breast cancers (2011) (202)
- ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 ) (2014) (201)
- Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. (2003) (197)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- HER2-Positive Circulating Tumor Cells in Breast Cancer (2011) (196)
- Facts and controversies in systemic treatment of metastatic breast cancer. (2004) (196)
- The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. (2000) (190)
- Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis (2018) (186)
- Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer (2006) (185)
- Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. (2005) (183)
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome (2014) (169)
- Emerging targeted agents in metastatic breast cancer (2013) (169)
- Comparison of prognostic gene expression signatures for breast cancer (2008) (164)
- Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. (2000) (162)
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
- Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. (2004) (155)
- Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. (2000) (154)
- Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. (2014) (153)
- Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. (2001) (152)
- Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. (2016) (151)
- The Predictive Value of HER2 in Breast Cancer (2001) (150)
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. (2008) (150)
- Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? (2002) (149)
- RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (140)
- Progress in adjuvant systemic therapy for breast cancer (2018) (139)
- Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. (1994) (138)
- A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. (1994) (138)
- Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
- The cardiotoxicity of anticancer agents. (1982) (134)
- Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. (2008) (133)
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer (2013) (133)
- A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck (1994) (131)
- HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel (2004) (131)
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO (2013) (128)
- Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. (1990) (127)
- Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations (2017) (127)
- Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. (1995) (127)
- TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. (2011) (126)
- Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (123)
- An overview of HER2. (2001) (121)
- Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. (2001) (120)
- International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. (2020) (118)
- The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. (1999) (116)
- Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. (2001) (116)
- Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. (2003) (116)
- Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice (2005) (116)
- HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. (2001) (112)
- Tumor‐infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome (1999) (112)
- Successful re-treatment with taxol after major hypersensitivity reactions. (1993) (112)
- Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. (2004) (110)
- Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. (1997) (110)
- Endocrine treatment in breast cancer: Cure, resistance and beyond. (2016) (110)
- Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy (2003) (109)
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2017) (105)
- Use of bisphosphonates in cancer patients. (1996) (105)
- What is the effect of systemic anticancer treatment on cognitive function? (2004) (104)
- A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. (2003) (104)
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond. (2018) (103)
- Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. (1993) (102)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 (2014) (101)
- Neoadjuvant therapy for breast cancer. (2015) (101)
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. (2021) (101)
- Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. (2013) (101)
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up (2021) (100)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2016) (100)
- Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. (2004) (100)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. (2007) (99)
- EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. (2002) (93)
- Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. (2000) (93)
- Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. (2006) (93)
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
- Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
- Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. (2003) (91)
- CD 4 + follicular helper T cell infiltration predicts breast cancer survival (2013) (91)
- Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. (2004) (90)
- Intraperitoneal chemotherapy: technical experience at five institutions. (1985) (90)
- Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. (2001) (90)
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
- First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group (2004) (85)
- Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
- Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. (2004) (84)
- A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease (2014) (83)
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2013) (82)
- Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues (2009) (81)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- The AURORA initiative for metastatic breast cancer (2014) (79)
- Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. (2002) (78)
- Chemotherapy for metastatic breast cancer-report of a European expert panel. (2002) (78)
- Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer (2006) (78)
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
- The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study (2012) (78)
- Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (2012) (77)
- Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. (2014) (77)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
- Six‐year results of a multimodality treatment strategy for locally advanced breast cancer (1988) (76)
- The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial (2009) (76)
- Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? (2003) (76)
- Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper (2014) (75)
- Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 (2013) (75)
- HER2/neu as a predictive factor in breast cancer. (2001) (74)
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
- Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing (2002) (73)
- The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data (2016) (73)
- Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (73)
- Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner (2006) (72)
- A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). (2006) (71)
- The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts (2010) (71)
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer (2012) (71)
- A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. (2012) (69)
- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. (2019) (68)
- Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. (2016) (68)
- Use of tumour markers in monitoring the course of ovarian cancer. (1999) (68)
- Resistance to trastuzumab: a necessary evil or a temporary challenge? (2002) (68)
- High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab (2014) (67)
- Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. (1996) (67)
- Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. (2006) (66)
- Current management of ovarian carcinosarcoma (2006) (66)
- Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology (2014) (66)
- Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. (2016) (66)
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) (65)
- Progress and new standards of care in the management of HER-2 positive breast cancer. (2007) (65)
- Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. (2004) (64)
- HER2-Low Breast Cancer: Molecular Characteristics and Prognosis (2021) (64)
- Beyond trastuzumab: new treatment options for HER2-positive breast cancer. (2011) (64)
- Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer (2009) (64)
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
- A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
- Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel (2008) (62)
- CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib (2017) (61)
- Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. (2000) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. (2013) (60)
- A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (2014) (60)
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients (2018) (59)
- p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (2007) (59)
- Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. (2013) (59)
- The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). (2014) (58)
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2017) (57)
- What clinicians need to know about antioestrogen resistance in breast cancer therapy. (2006) (57)
- HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients? (2000) (56)
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results (2015) (56)
- A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. (2008) (56)
- Biology of breast cancer during pregnancy using genomic profiling. (2014) (55)
- Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. (2002) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
- Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer (2004) (54)
- Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. (2003) (54)
- The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? (2000) (54)
- Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. (2004) (53)
- Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial (2018) (53)
- LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (53)
- Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. (2018) (53)
- A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. (1994) (52)
- Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. (2002) (52)
- A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. (2000) (52)
- Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. (2000) (52)
- A fuzzy gene expression-based computational approach improves breast cancer prognostication (2010) (52)
- Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment (2012) (51)
- Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). (2004) (51)
- Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. (2004) (51)
- Immunotherapy for early breast cancer: too soon, too superficial, or just right? (2020) (51)
- First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. (2004) (50)
- A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). (2014) (50)
- Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study (2021) (49)
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer (2015) (49)
- Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients (2006) (49)
- HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 (2017) (49)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (49)
- Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. (2010) (48)
- Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). (2007) (48)
- Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial (2000) (48)
- Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes. (2013) (47)
- New approaches for improving outcomes in breast cancer in Europe. (2015) (47)
- Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (47)
- Motherhood after breast cancer: searching for la dolce vita (2011) (47)
- HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. (2008) (47)
- The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. (2007) (46)
- Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH (2009) (46)
- Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. (2005) (46)
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
- Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient’s Body Mass Index (2018) (46)
- Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. (2016) (45)
- Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. (2008) (45)
- Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS) (2010) (45)
- Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study (2008) (45)
- HER-2 as a Target for Breast Cancer Therapy (2009) (44)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2018) (44)
- Phase II study of vinorelbine in patients with androgen-independent prostate cancer. (2001) (44)
- The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
- Florence statement on breast cancer, 1998 forging the way ahead for more research on and better care in breast cancer. (1999) (43)
- ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials (2020) (43)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2019) (42)
- S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. (2011) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- The evolution of treatment strategies: aiming at the target. (2007) (42)
- Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review (2019) (42)
- Bringing molecular prognosis and prediction to the clinic. (2005) (41)
- Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. (2016) (41)
- Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. (2013) (40)
- Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (2016) (40)
- Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. (2020) (40)
- Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) (2017) (40)
- Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. (2006) (40)
- Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). (2001) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials (2018) (39)
- The EORTC Breast Cancer Group: 40 years of research contributing to improve breast cancer management. (2002) (39)
- Genomic grade adds prognostic value in invasive lobular carcinoma. (2013) (39)
- Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers (2018) (38)
- Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. (2008) (37)
- Moving Forward: Herceptin® in the Adjuvant Setting (2002) (37)
- Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions (2012) (37)
- A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. (2007) (37)
- Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells (2020) (36)
- Recurrence dynamics of breast cancer according to baseline body mass index. (2017) (36)
- Doxorubicin/paclitaxel (2023) (36)
- Taxanes in the adjuvant treatment of breast cancer: why not yet? (2001) (36)
- The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer (2004) (35)
- A new standard of care for treatment of ovarian cancer. (2000) (34)
- Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites (2003) (34)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
- Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy (2016) (34)
- Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center. (1995) (34)
- Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial (2019) (33)
- Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. (2015) (33)
- Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
- An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer. (1995) (32)
- Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. (2016) (31)
- Adjuvant chemotherapy in 2005: standards and beyond. (2005) (31)
- Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (2019) (31)
- A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). (2016) (31)
- Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors (2012) (31)
- New cytostatic drugs in ovarian cancer. (1993) (30)
- PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? (2019) (29)
- Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. (2017) (29)
- Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up? (2014) (29)
- Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis (2013) (29)
- Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives (2019) (29)
- Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. (2004) (28)
- Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). (2006) (28)
- Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. (2020) (28)
- Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial (2019) (27)
- D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study (2001) (27)
- Personalized therapy for breast cancer: a dream or a reality? (2013) (27)
- Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). (2019) (27)
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. (2019) (27)
- Monoclonal Antibody-Based Targeted Therapy in Breast Cancer (2012) (27)
- Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. (2001) (27)
- Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy (2009) (26)
- Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study (2022) (26)
- Hurdles and delays in access to anti-cancer drugs in Europe (2014) (26)
- Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. (2019) (26)
- Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule. (1982) (26)
- Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. (2000) (26)
- Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics". (2014) (26)
- Tumour stimulating effects of recombinant human interleukin-6 (1994) (25)
- Use and abuse of taxanes in the management of metastatic breast cancer. (2003) (25)
- Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment (1992) (25)
- The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. (2016) (25)
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (2014) (25)
- A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. (2008) (25)
- Intravenous pamidronate in patients with tumor‐induced osteolysis: A biochemical dose‐response study (1995) (25)
- Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring (2021) (25)
- The current use and attitudes towards tumor genome sequencing in breast cancer (2016) (24)
- Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy (2020) (23)
- The Hamburg statement: the partnership driving the European agenda on breast cancer. (2004) (23)
- Keeping faith with trial volunteers (2007) (23)
- HER2-overexpressing breast cancer: time for the cure with less chemotherapy? (2011) (23)
- Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. (2015) (23)
- Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . (2013) (23)
- A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. (2000) (23)
- A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. (2000) (22)
- Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. (2003) (22)
- Frequent incidence of BARD1‐truncating mutations in germline DNA from triple‐negative breast cancer patients (2016) (22)
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. (2016) (22)
- Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen. (1987) (21)
- Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe? (2011) (21)
- Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). (2006) (21)
- What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? (2020) (21)
- Risk factors for the development of brain metastases in patients with HER2-positive breast cancer (2018) (21)
- LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) (2017) (21)
- Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations (2018) (21)
- Pattern of care in locally advanced breast cancer: focus on local therapy. (2011) (21)
- Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer (2012) (21)
- Molecular forecasting of breast cancer: time to move forward with clinical testing. (2006) (20)
- Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial (2011) (20)
- 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2 (2014) (20)
- Taxotere toxicity — Protective effects of premedication (1993) (20)
- First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group (2004) (20)
- Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. (2009) (20)
- ESR1 mutations in metastatic lobular breast cancer patients (2019) (20)
- A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. (2006) (20)
- Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. (2001) (20)
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
- Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. (2009) (20)
- New data on chemotherapy in the adjuvant setting. (2003) (20)
- Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. (1995) (19)
- ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer (2005) (19)
- Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules (2017) (19)
- Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE (2013) (18)
- Use of trastuzumab for the treatment of early stage breast cancer (2006) (18)
- The pipeline of new anticancer agents for breast cancer treatment in 2003. (2003) (18)
- Neoadjuvant treatment: the future of patients with breast cancer (2018) (18)
- Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. (2015) (18)
- Remaining controversies in the upfront management of advanced ovarian cancer (2004) (18)
- Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
- 348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC) (1995) (18)
- An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. (2014) (18)
- Reducing the global breast cancer burden: the importance of patterns of care research. (2005) (18)
- Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer (2013) (17)
- Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881 (1998) (17)
- First-Line Treatment of Metastatic Breast Cancer (2006) (17)
- The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer (2015) (17)
- A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. (2004) (17)
- Progesterone receptor testing: not the right time to be buried. (2005) (17)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (17)
- Adjuvant therapy in elderly patients with breast cancer. (2004) (17)
- The best use of chemotherapy in the adjuvant setting. (2003) (17)
- Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer (2016) (16)
- Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934). (1981) (16)
- Expression of c-erbB2, TGF-β1 and pS2 genes in primary human breast cancers (1992) (16)
- Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2013) (16)
- Brussels Statement document. (2001) (16)
- Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. (2020) (16)
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. (2022) (16)
- Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer (2005) (16)
- Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients (2020) (16)
- Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial (2020) (16)
- Optimising chemotherapy dose density and dose intensity (2000) (16)
- Systemic treatment of patients with early breast cancer: recent updates and state of the art. (2019) (16)
- Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial (2017) (16)
- New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective (2004) (16)
- Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos (2020) (16)
- Docetaxel: a new defence in the management of breast cancer (1995) (16)
- Metastatic breast cancer: The Odyssey of personalization (2016) (16)
- Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002 (2002) (16)
- Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome (2020) (16)
- Estrogen receptor status and estradiol sensitivity of MCF-7 cells in exponential growth phase. (1988) (15)
- HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. (2002) (15)
- Will the dark sky over advanced renal cell carcinoma soon become brighter? (2005) (15)
- Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring (2005) (15)
- Adjuvant systemic therapy in breast cancer: quo vadis? (2015) (15)
- Progress in systemic therapy for breast cancer: an overview and perspectives (2003) (15)
- Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs (2016) (15)
- Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy (2021) (15)
- Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma (2008) (15)
- A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. (2007) (14)
- New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors (2014) (14)
- Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. (2017) (14)
- Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). (2006) (14)
- Ureteral obstruction in patients with breast cancer (1988) (13)
- Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. (2004) (13)
- Post-Mastectomy Radiation Therapy in HER-2 Positive Breast Cancer Patients: Analysis of the HERA Trial. (2020) (13)
- Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial (2020) (13)
- Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule (1999) (13)
- Potential Role of Oral Anthracyclines in Older Patients with Cancer (1994) (13)
- An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer. (2003) (13)
- Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. (1991) (13)
- State-of-the-art chemotherapy for advanced breast cancer. (2000) (13)
- Adjuvant systemic therapy for breast cancer. (1995) (13)
- Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial (2020) (13)
- Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors (2020) (13)
- ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL (2012) (13)
- Closing remarks and treatment guidelines. (2001) (13)
- Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers (2004) (13)
- Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story? (2005) (12)
- Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. (2018) (12)
- Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. (2002) (12)
- Are we HER-ting for innovation in neoadjuvant breast cancer trial design? (2009) (12)
- Simultaneous targeting of estrogen receptor and HER2 in breast cancer (2010) (12)
- Optimizing Anthracycline Therapy for Node Positive Breast Cancer (2002) (12)
- An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. (2003) (12)
- Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up (2012) (12)
- The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. (2018) (12)
- The Breast International Group. a new spirit of collaboration in breast cancer research for the new millennium. (2000) (12)
- Targeted adjuvant therapy in breast cancer (2016) (12)
- Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis (2020) (12)
- Genomic grade adds prognostic value in invasive lobular carcinoma. (2013) (12)
- p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. (2017) (12)
- ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers (2016) (12)
- Future perspectives of docetaxel (Taxotere) in front-line therapy. (1997) (12)
- A Meta-Analysis of Gene Expression Profiling Studies Identifies Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer. (2009) (12)
- Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes (2017) (12)
- Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer. (1999) (12)
- Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. (2020) (12)
- 347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC) (1995) (12)
- Treatment of advanced breast cancer: current status (1996) (12)
- Optimising chemotherapy dose density and dose intensity. new strategies to improve outcomes in adjuvant therapy for breast cancer. (2000) (12)
- Breast cancer gene expression profiling: clinical trial and practice implications. (2005) (12)
- A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study (1998) (11)
- Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. (2014) (11)
- Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis (2016) (11)
- Gene profiling assay and application: the predictive role in primary therapy. (2011) (11)
- Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial (2015) (11)
- Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. (2021) (11)
- Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma (1999) (11)
- Clinical phase I trial of marcellomycin with a single-dose schedule. (1983) (11)
- 42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING (2013) (11)
- Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial. (2004) (10)
- Advanced ovarian cancer. Dose intensity. (1993) (10)
- Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. (2011) (10)
- Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. (2021) (10)
- PIK 3 CA Genotype and a PIK 3 CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2012) (10)
- Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. (2005) (10)
- Phase I clinical trial with ametantrone (NSC-287513). (1981) (10)
- Comparison of tritiated estradiol and tamoxifen aziridine for measurement of estrogen receptors in human breast cancer cytosols. (1991) (10)
- Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer (2005) (10)
- Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients (2004) (10)
- The future of breast cancer research in danger. (2002) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts). (2019) (10)
- Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. (2020) (10)
- 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC) (2020) (9)
- Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA (2017) (9)
- ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer. (2019) (9)
- 215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2017) (9)
- Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era (2002) (9)
- VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up (2022) (9)
- Correcetions to "A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)". (2017) (9)
- Intergroup collaboration in ovarian cancer: a giant step forward (1999) (9)
- Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (2015) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Why your preferred targeted drugs may become unaffordable. (2013) (9)
- Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). (2011) (8)
- Intergroup collaboration in ovarian cancer: a giant step forward. (1999) (8)
- Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021. (2009) (8)
- Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. (1988) (8)
- Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. (1997) (8)
- Novel therapeutics in breast cancer—Looking to the future (2009) (8)
- Evolution towards hormone independence of the MXT mouse mammary tumor is associated with a gradual change in its estrogen receptor molecular polymorphism. (1998) (8)
- Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium (2012) (8)
- An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer (2001) (8)
- Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group. (1994) (8)
- 253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial (2012) (8)
- Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. (2011) (8)
- A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer. (2001) (8)
- Comments on the treatment of breast cancer. (1986) (8)
- Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X (2020) (8)
- Conclusions: future strategies in the treatment of breast cancer. (1997) (7)
- Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO). (2014) (7)
- Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. (2002) (7)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
- Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents. (2000) (7)
- Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. (2002) (7)
- Taxoid compounds in breast cancer: current status and future prospects. (1995) (7)
- The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. (2002) (7)
- Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. (2004) (7)
- Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. (2020) (7)
- Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations☆ (2021) (7)
- Tamoxifen aziridine labeling of the estrogen receptor — potential utility in detecting biologically aggressive breast tumors (2005) (7)
- Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer (2002) (7)
- Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors (2009) (7)
- Tumor dormancy at bedside: A late awakening. (2019) (7)
- 381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors (2004) (7)
- An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. (2002) (7)
- Doxorubicin-paclitaxel - A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial (2003) (7)
- Breast cancer: new aspects of adjuvant hormonal therapy. (2000) (7)
- Abstract 4564: Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial. (2013) (7)
- Mitomycin C and Vinblastine in combination with Amifostine in metastatic breast cancer (1997) (7)
- Liquid biopsy to test new treatment strategies in breast cancer: are we there yet? (2012) (7)
- A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors 1 (2000) (7)
- Flexible care in breast cancer. (2021) (7)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (7)
- Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. (2010) (7)
- Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial (2021) (7)
- Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. (2021) (7)
- Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial (2020) (7)
- Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts). (2004) (6)
- 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. (2002) (6)
- [Breast cancer and herceptin]. (2000) (6)
- Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors. (2005) (6)
- EORTC 10968; Phase I study of CaelyxTM at a six week interval in patients with metastatic breast cancer (1998) (6)
- Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial (2022) (6)
- Clinical and Pharmacokinetic Studies on the New Platinum Complex Zeniplatin (CL286,558) (1991) (6)
- Kinetics of adenosine 3':5'-monophosphate accumulation in dog thyroid slices. (1976) (6)
- 444 The EORTC 10041/BIG 03–04 MINDACT trial is feasible: first results of the pilot phase (2010) (6)
- Systemic therapy for early-stage breast cancer: learning from the past to build the future (2022) (6)
- 150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy (2017) (6)
- The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoaltto Trial (BIG 1-06) (2012) (6)
- Vorozole (Rivizor™): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure (1998) (6)
- Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer (2003) (6)
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
- Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer (2020) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy (2003) (6)
- Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial (2016) (6)
- Abstract 986: Unraveling breast cancer progression through geographical and temporal sequencing (2014) (6)
- Evaluation of Microtubule Associated Parameters (MTAPs) as predictive markers for Advanced Breast Cancer (ABC) patients treated with docetaxel (2001) (5)
- Tumor infiltrating lymphocytes and tertiary lymphoid structures in paired primary tumors and metastases from breast cancer patients (2016) (5)
- Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies. (2004) (5)
- Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
- Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. (2021) (5)
- A phase I trial of a new antiemetic drug--clebopride malate--in cisplatin-treated patients. (1992) (5)
- De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost? (2020) (5)
- Identi ® cation and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in ® rst-line chemotherapy in advanced breast cancer (2000) (5)
- Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial (2021) (5)
- Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis (2021) (5)
- Abstract PD2-04: Baseline circulatingESR1mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer (2019) (5)
- Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP) (2013) (5)
- Inadvertent transfer of choriocarcinoma with renal transplantation: characteristics of the donor-recipient pairs. (1995) (5)
- 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2021) (5)
- Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer (2021) (5)
- Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (5)
- Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study (2001) (5)
- Non-endocrine systemic therapies in advanced breast cancer (2003) (5)
- A prospective study of the correlation between Ca 125 serum levels and surgically verified tumor burden in ovarian cancer (OV-CA) patients (PTS) (1985) (5)
- A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. (2012) (5)
- Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2018) (5)
- A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. (2021) (5)
- Long-term survival in pituitary metastasis from breast cancer. (2006) (5)
- Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. (2022) (5)
- Gene expression profiling in breast cancer challenges the existence of intermediate histological grade (2005) (5)
- Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2018) (5)
- High quality gene expression microarray data from a multicentre prospective trial: results of the first microarray analysis in the EORTC 10994/BIG 00–01 study (2004) (5)
- Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors (2004) (5)
- Original article: A phase I trial of a new antiemetic drug—clebopnde malate—in cisplatin-treated patients (1992) (5)
- STAT3 activation in HER2‐positive breast cancers: Analysis of data from a large prospective trial (2020) (5)
- A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer (2008) (5)
- Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want. (2020) (5)
- Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer. The NOCOVA (1997) (5)
- New cytotoxic agents. (1997) (5)
- Optimal adjuvant cytotoxic therapy for breast cancer (2001) (4)
- A phase II study of taxotere in patients with advanced head and neck cancer (1993) (4)
- Cancer drugs, survival and ethics: a critical look from the inside (2016) (4)
- Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al. (2016) (4)
- Taxotere in advanced malignant melanoma: A fase-II trial of the eortc early clinical trials group (1993) (4)
- Code of practice needed for samples donated by trial participants. (2022) (4)
- Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies (2020) (4)
- PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) (1996) (4)
- Standard medical treatment for early breast cancer. (2001) (4)
- Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N) (1997) (4)
- Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial (2019) (4)
- Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
- Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. (2004) (4)
- Preliminary Experience with Marcellomycin: Preclinical and Clinical Aspects (1982) (4)
- Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
- S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse. (2011) (4)
- Unusual presentation of nasopharyngeal carcinoma with rectal metastasis (2017) (4)
- Limited Clinical Utility of Prognostic Gene Expression Profiles in Grade 3 Node-Negative Early Stage Breast Cancer. (2009) (4)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
- ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer (2019) (4)
- HER 2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER 2 (2017) (4)
- BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. (2009) (4)
- Personalised cancer management: closer, but not here yet. (2013) (4)
- Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): An EORTC randomized study with crossover (1997) (4)
- Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures (2006) (4)
- The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual (2011) (4)
- Erratum: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (2009) (4)
- Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr (2016) (4)
- HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy (2007) (4)
- Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial (2013) (4)
- Breast cancer therapies in development. A review of their pharmacology and clinical potential. (1997) (4)
- A study of molecular markers with potential prognostic and predictive value (c-erb b-2, p53, cyclin D1, MIB1, ER and PgR) in locally advanced breast cancer treated with neo-adjuvant dose intensive chemotherapy in an EORTC-NCIC-SAKK randomized phase III study (1998) (4)
- PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer (2022) (4)
- Phase I trial of pemetrexed plus paclitaxel administered every 21 days in patients with advanced solid tumors. (2004) (4)
- 319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection (2020) (4)
- Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer (2004) (4)
- Meta-analysis of the cardiac events in the adjuvant trastuzumab trials. (2018) (4)
- Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology (2014) (4)
- Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis (2022) (4)
- Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent (2007) (3)
- Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers. (1992) (3)
- Adjuvant treatment of early breast cancer (2005) (3)
- Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC) (2007) (3)
- Molecular qRT-PCR grade index: a new tool for breast cancer (BC) patient grading improvement (2008) (3)
- EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer (2000) (3)
- Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer (BOLERO-2): Effect of Visceral Metastases and Prior Endocrine Therapy (2012) (3)
- A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2* (2006) (3)
- SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). (2019) (3)
- The EORTC-Breast Cancer Cooperative Group clinical research programme in early breast cancer. EORTC-BCCG. (1998) (3)
- Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
- E1. Tailored systemic treatment for breast cancer: dream or reality? (2004) (3)
- Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study (2012) (3)
- 3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial (2012) (3)
- Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group. (1989) (3)
- Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study (1991) (3)
- Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group). (1998) (3)
- INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY (2003) (3)
- Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results (2005) (3)
- 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01) (2021) (3)
- Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial (2010) (3)
- Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature (2018) (3)
- 14O_PR Biology of Breast Cancer Diagnosed in Young Women: Pooled Gene Expression Analysis From 3522 Patients (2012) (3)
- P1-02-05: Invasive Lobular Carcinoma – A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features. (2011) (3)
- Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer. (2002) (3)
- P4-16-04: An Open-Label, Phase IIa, Non-Randomized Study of Radium-223 in Breast Cancer Patients with Bone Dominant Disease No Longer Considered Suitable for Endocrine Therapy. (2011) (3)
- Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial. (2019) (2)
- Integrate: a new model in collaborative breast cancer research (2011) (2)
- Proceedings of Patient Reported Outcome Measures (PROMs) Conference Birmingham 2018 (2018) (2)
- EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. (1997) (2)
- Phase II study of the eortc breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) — preliminary results (1993) (2)
- SERIOUS ADVERSE EVENTS AMONG OLDER PATIENTS IN THE ALTTO TRIAL (2019) (2)
- Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial (2021) (2)
- Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995 (2007) (2)
- Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling. (2011) (2)
- Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2015) (2)
- Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. (2010) (2)
- [Towards an individualization of systemic treatment of breast tumors]. (2006) (2)
- N-(Phosphonacetyl)-L-aspartate (PALA): current status. (1980) (2)
- Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis (2013) (2)
- Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer (2005) (2)
- Breast cancer. (1998) (2)
- Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report (2015) (2)
- Intraperitoneal chemotherapy: belly-bath or pain-in-the-side? (1987) (2)
- Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer (2017) (2)
- Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations (2017) (2)
- P1-07-08: PCR Genomic Grade in Breast Cancer: A New Tool for Daily Practice. (2011) (2)
- Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the PePiTA study. (2019) (2)
- Meta-analysis of taxanes alone or in combination with anthracyclines versus non taxane-based regimens as first-line therapy of patients with metastatic breast cancer (MBC): a lesson from the past and a message for the future (2006) (2)
- Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (2011) (2)
- Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". (2019) (2)
- 1387PD_PRARE LIFE-SAVING ANTICANCER DRUGS REACHING ALL PATIENTS? PATTERNS AND DISCREPANCIES OF TRASTUZUMAB USE IN THE EUROPEAN UNION AND THE USA (2014) (2)
- Management of early breast cancer in patients bearing germline BRCA mutations. (2020) (2)
- Abstract P2-03-01: Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial (2015) (2)
- Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
- Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) based chemotherapy (2002) (2)
- Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel (AT) in the adjuvant treatment of breast cancer (BC) (1998) (2)
- Ovarian cancer: new therapeutic concepts, renewed optimism. (1985) (2)
- The Src inhibitor dasatinib inhibits breast cancer cell growth in vitro and exerts synergistic effects with bisphosphonates (2008) (2)
- Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial (2021) (2)
- LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC) (2022) (2)
- Abstract P6-04-13: The role of precision medicine in "real-life" management of breast cancer patients: A survey assessing the current use and attitudes towards tumor molecular sequencing in clinical practice (2016) (2)
- Routine follow-up of patients following primary therapy for early breast cancer: what is useful? (1993) (2)
- Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial (2018) (2)
- Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. (2010) (2)
- Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. (1992) (2)
- HER-2 amplification evaluated by fluorescence in-situ hybridization (FISH) as a predictive marker in node-positive (N+) breast cancer (BC) patients (pts) randomly treated with CMF or an anthracycline-based therapy (2001) (2)
- LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
- 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC) (2020) (2)
- 22P BCL2 Negative Breast Tumors but not Axillary Lymph Nodes Predict a Better Overall Survival in Patients Treated with Higher Doses of Epirubicin at a Median follow-up of 15.6 Years (2012) (2)
- Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen (2005) (2)
- Molecular characterization of early-stage her2-overexpressing breast cancer (her2+ bc) treated with adjuvant trastuzumab: identification of prognostic groups (2012) (2)
- nab TM-Paclitaxel : A Targeted Chemotherapy to Improve Outcomes in Metastatic Breast Cancer (2)
- Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer) (2021) (2)
- [Epithelial ovarian cancer: a challenge in gynecologic oncology]. (1992) (2)
- Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study (2014) (2)
- Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study (1998) (2)
- [Optimal therapeutic strategies in ovarian epithelial cancer in 1997]. (1997) (1)
- 1835 Health-related quality of life in advanced breast cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials (2015) (1)
- The EORTC strategy for the early 2000's. (2000) (1)
- PP-7-12 Dose-finding study of weekly oral vinorelbine (VRL) in patients (PTS) with advanced breast cancer (ABC): preliminary results (1996) (1)
- Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial. (2012) (1)
- Introduction. Herceptin: HER2 status--changing clinical practice. (2001) (1)
- Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen-receptor (ER) negative breast cancer (BC) patients. (2007) (1)
- Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 (2019) (1)
- P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01). (2009) (1)
- Abstract P1-10-12: Differential benefit of intra-operative administration of ketorolac on breast cancer disease recurrence according to baseline body mass index (2018) (1)
- Abstract P2-15-04: Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: The HERA trial experience (2013) (1)
- Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? (2011) (1)
- PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG (1996) (1)
- Consensus Statement A new standard of care for treatment of ovarian cancer (2000) (1)
- ["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"]. (1998) (1)
- Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06) (2017) (1)
- Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (2018) (1)
- Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer. (2003) (1)
- 210 Anthracyclines and topoisomerase II alpha – what is beyond? (2010) (1)
- Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial (2022) (1)
- Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (2016) (1)
- 70-Gene Signature in Early-Stage Breast Cancer. (2016) (1)
- Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial (2018) (1)
- Oxaliplatin and 5-fluorouracil in heavily pretreated patients with ovarian carcinoma: A well tolerated and efficient treatment (2007) (1)
- Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (1)
- 170P β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial (2020) (1)
- Abstract PD1-7: Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) evaluation in the NeoALTTO trial (BIG 01-06) (2013) (1)
- Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. (2019) (1)
- Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen (2005) (1)
- Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2019) (1)
- AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
- CD10 expression and risk of relapse in DCIS. (2009) (1)
- RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (1)
- Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
- ESR1 mutations in metastatic lobular breast cancer patients (2019) (1)
- BIG — The breast intergroup (1998) (1)
- Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13) (2023) (1)
- RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. (2018) (1)
- Personalized medicine for breast cancer: dream or reality? (2013) (1)
- A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer (2005) (1)
- P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC). (2011) (1)
- CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. (2019) (1)
- Abstract OT1-18-02: First-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: Preliminary results of the randomized phase II SYNERGY trial (2022) (1)
- Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer. (2019) (1)
- Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. (2021) (1)
- ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE , HER 2-NEGATIVE EARLY STAGE BREAST CANCER (2012) (1)
- Her 2 and topoisomerase (TOPO)IIα as predictive markers for node-positive (N+) breast cancer (BC) patients (PTS) randomised to adjuvant CMF or epirubicin (E) — cyclophosphamide (C) (1999) (1)
- CCR New Strategies New Strategies in Breast Cancer : The Signi fi cance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T 1 a , bN 0 M 0 Tumors (2014) (1)
- Capecitabine as adjuvant therapy for elderly breast cancer (BC) patients (pts): a pilot study (2006) (1)
- International Breast Cancer Research: Launching an Expedition to the Moon. (2009) (1)
- Promising activity with eniluracil (776C85) and oral 5-fluorouracil in patients with anthracycline-refractory of anthracycline- and taxane-refractory advanced breast cancer: a phase II study (1999) (1)
- Stroma related gene signature predicts sensitivity to epirubicin containing neoadjuvant chemotherapy. A microarray study of 102 patients included in EORTC 10994/BIG 00-01 trial (2006) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Abstract P6-07-02: CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib (2016) (1)
- Abstract P6-07-22: Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer (BC): a pooledin-silicoanalysis (2012) (1)
- Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2020) (1)
- Abstract S1-02: Lymphocytic infiltration in invasive lobular breast cancer (2016) (1)
- PIK3CA, AKT1 MUTATION AND HER2 AMPLIFICATION GENE SIGNATURES (GS) SUGGEST PREDOMINANTLY NEGATIVE FEEDBACK INHIBITION OF PI3K/AKT PATHWAY IN HUMAN BREAST CANCER (BC). (2009) (1)
- Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer (2018) (1)
- Abstract PD3-7: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer (2015) (1)
- Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) (2020) (1)
- Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer (2021) (1)
- p-STAT 3 in luminal breast cancer : Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial (2017) (1)
- Abstract S2-05: Characterization and clinical relevance of the genomic alterations defining lobular breast cancer (2015) (1)
- Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. (2022) (1)
- Breast cancer in 2015: Academic research sheds light on issues that matter to patients (2016) (1)
- Closing remarks and treatment guidelines. (2001) (1)
- Abstract S3-02: Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO (2017) (1)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (1)
- Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer (2018) (1)
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From BOLERO-2 (2015) (1)
- Decreased CD10 Expression Is Associated with a Higher Risk of Relapse in Ductal Carcinoma In Situ (DCIS). (2009) (1)
- Abstract LB-180: Epigenetic portraits of human breast cancers (2011) (1)
- Abstract GS1-06: Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples (2019) (1)
- Abstract P5-01-02: Characterization of follicular helper CD4 T cells and B cells resident in peritumoral tertiary lymphocyte structures as specific markers for an immunological grade in breast cancer (2013) (1)
- 372 Neo-adjuvant chemotherapy in locally advanced beast cancer (LABC): FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (Filgrastim). An EORTC—NCIC—SAKK study. Preliminary results of dose intensity (DI) (1995) (1)
- Comprar Textbook of Medical Oncology. 4th Ed. | James O. Armitage | 9780415477482 | Informa Healthcare (2009) (1)
- P1-07-06: High Concordance of Protein (by IHC), Gene (by FISH; HER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial. (2011) (1)
- 346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover (1995) (1)
- The future of breast cancer research and practice in Asia, Latin America, and the Middle East/North Africa: a qualitative horizon scanning analysis. (2009) (1)
- 109P Updated Results of the Bolero-2 Phase Iii Trial Evaluating Everolimus (Eve) for Postmenopausal Women with Advanced Breast Cancer (Abc) (2012) (1)
- International study on inter-reader variability for circulating tumor cells in breast cancer (2014) (1)
- Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial (2020) (1)
- Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007. (2008) (1)
- Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance). (2019) (1)
- Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: Tailoring treatment in hormone responsive breast cancer (2007) (1)
- Adjuvant Breast Cancer Treatment : Evolution or Revolution ? (2005) (1)
- Preoperative Axillary Immunolymphoscintigraphy (ilsc) in Breast-cancer Patients Using a 123-iodine Labeled Monoclonal-antibody (ab) (1992) (1)
- HER2-targeted therapy (2010) (1)
- 412 The EORTC 10041/BIG 03-04 MINDACT Trial Quality Assurance Program – Results of the Questionnaire for Pathologists (2012) (1)
- PP-8-15 Phase II studies with Rlvfzor® (Vorozole) in Advanced Breast Cancer (1996) (1)
- Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial (2020) (1)
- 98 POSTER A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors (2006) (1)
- Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome (2012) (1)
- SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry (2023) (0)
- Special focus on cardiac toxicity from a pilot study of the adjuvant sequencing chemotherapy of doxorubicin/docetaxel/CMF regimen and radiotherapy with a mid-term follow-up in patients treated for poor prognosis breast cancer (2004) (0)
- Activation of the tumour suppressor PTEN as an alternative explanation for Trastuzumab’s mechanism of action (2005) (0)
- Sequential adrlamycin (A), docetaxel (D) and CMF in the adjuvant treatment (AT) of breast cancer (BC) (1997) (0)
- 131P Impact of body mass (BMI) and weight change after adjuvant treatment in patients (pts) with HER2-positive early breast cancer (2021) (0)
- Regarding the dilemma of adjuvant therapy in postmenopausal patients with node-positive, estrogen receptor-positive breast cancer: are we better informed? (1995) (0)
- 64 The prognostic and predictive role of HER-2 and topoisomerase II alpha in breast cancer (BC) (2003) (0)
- Abstract PD4-06: PD4-06 Obesity-associated changes in transcriptomic profile and immune landscape of primary breast cancer revealed by bulk and single-cell gene expression data (2023) (0)
- Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer (2018) (0)
- [Local growth factors for breast cancer: general review and potential value for clinician]. (1991) (0)
- Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al. (2018) (0)
- Abstract OT1-3-02: The treat CTC trial – A new approach targeting circulating tumor cells (CTC) in early breast cancer (EBC) (2013) (0)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (0)
- Abstract P4-09-05: Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials (2023) (0)
- Abstract BL2: Lessons learned from an expedition exploring the world of HER2 positive breast cancer (2016) (0)
- PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer (2022) (0)
- Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program (2020) (0)
- Abstract P1-01-10: Exome sequencing of circulating tumor cells in metastatic breast cancer (2017) (0)
- Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (0)
- Abstract PD4-06: Investigation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI) (2017) (0)
- Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients (2020) (0)
- The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study. Results of an EORTC — NCIC — SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC) (1999) (0)
- PP-7-1 phase II study of liarozole in advanced breast cancer patients (1996) (0)
- European academics fight for the health of clinical trials (2014) (0)
- 25OpSTAT3 in luminal breast cancer. Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial (2017) (0)
- Retrospective Analysis of Advanced Luminal Breast Cancer Patients Treated with Endocrine Therapy (ET) and Palbociclib Within a Compassionate Use Programme (2017) (0)
- Treatment of triple negative breast cancer receptors (2007) (0)
- Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'. (2017) (0)
- PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? (2019) (0)
- Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial (2019) (0)
- Abstract SY45-02: Evaluation of targeted therapies in advanced breast cancer (2014) (0)
- Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer (2012) (0)
- A substantial change in breast cancer (BC) biology arises after 50 years old regardless of patient (pt) menopausal status (2007) (0)
- Abstract P1-07-02: Withdrawn (2018) (0)
- Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2015) (0)
- 1137 Implementation of new biological knowledge into cancer management (2003) (0)
- [Has the time arrived for gene expression use at the bedside?]. (2008) (0)
- Title: The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data (2016) (0)
- P30 The Jules Bordet Onco-Geriatric Pilot Unit: one-year report (2009) (0)
- Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio. (2017) (0)
- [In vitro determination of the antitumor activity of chemotherapy]. (1983) (0)
- Anti receptor antibodies: Update of their current role in the treatment of breast cancer (2002) (0)
- Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression (2005) (0)
- Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas (2018) (0)
- Abstract P6-11-16: PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer (2017) (0)
- Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations (2013) (0)
- Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (2021) (0)
- Abstract P1-13-09: Withdrawn (2018) (0)
- P4-07-14: Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by CellSearch® in Non-Metastatic Breast Cancer: An International Ring Study To Assess Inter-Reader Variability. (2011) (0)
- Abstract A124: Tertiary lymphoid structures: Predictors of effective antitumor immunity in human breast cancer? (2016) (0)
- Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer (2010) (0)
- ESMO-CSCO - Building the clinical trials of the future (2012) (0)
- E12. Progress in systematic therapy for breast cancer (2002) (0)
- 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial (2022) (0)
- Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. (2018) (0)
- Expanding our knowledge of breast cancer biology: Will it impact on patient management? (1998) (0)
- SY-8-3 New drugs other than chemotherapeutic or hormonal agents: The hope for innovative treatment strategies against breast cancer (1996) (0)
- 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial (2022) (0)
- New drugs and new strategies for women with breast cancer (1997) (0)
- Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): Analysis from NeoALLTO trial (2016) (0)
- Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial (2021) (0)
- Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials” (2020) (0)
- 98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase (2022) (0)
- Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2019) (0)
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
- The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET). (2004) (0)
- Expression of c-erbB 2 , TGF-131 and pS 2 Genes in Primary Human Breast Cancers (2005) (0)
- Abstract ES4-3: Can we improve treatment tailoring in advanced HER2+ breast cancer? (2018) (0)
- p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials (2009) (0)
- Clinical trials 101: information for basic and translational researchers. (2009) (0)
- Same Story with Different Endings in HER2-Positive Breast Cancer: Why the Benefit ofPertuzumab is Robust in the Metastatic Scenarioand Modest in the Adjuvant Setting? (2020) (0)
- Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial (2017) (0)
- HER2 State-of-the-Art Conference, 21-23 November 1999 - Montreux, Switzerland, workshop proceedings (2001) (0)
- Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy (2022) (0)
- Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens (2004) (0)
- Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial (2021) (0)
- Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial (2020) (0)
- PP-6-24 A Retrospective Analysis of 124 Cases on the Different Clinical Outcome for Patients with ER−/PR+ Breast Tumors as Compared with ER−/PR− (1996) (0)
- # 3016 - Definition of Clinically Distinct Subtypes Within Estrogen Receptor Positive Luminal Breast Carcinomas (2005) (0)
- 322TiPPYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer (2017) (0)
- Abstract P1-07-11: Risk factors for the development of brain metastases (BM) in 506 patients with HER2-positive breast cancer (HER2+ BC): A single institutional retrospective analysis (2018) (0)
- 43: Cancer of the breast, Martine Piccart, Toral Gathani, Dimitrios Zardavas, Hatem A. Azim Jr., Christos Sotiriou, Giuseppe Viale, Emiel J T Rutgers, Mechthild Krause, Monica Arnedos, Suzette Delaloge, Fabrice Andre, and Felipe Ades (2015) (0)
- Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study (2022) (0)
- Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations (2018) (0)
- 1 BACKGROUND AND IMPLEMENTATION PLAN FOR THE EUROPEAN CANCER PATIENT’S BILL OF RIGHTS, 2016 (ARCHIVE) ECC Members (2017) (0)
- Further biochemical characterization of an EP-PGR+ breast cancer cell line (1990) (0)
- Interpretation Dose-intensive treatment only has a temporary effect on HRQOL, thus enabling more research on intensive treatment for patients with locally advanced breast cancer. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled (2005) (0)
- Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study (2014) (0)
- Baseline anemia (BA) as a predictor of response to first line chemotherapy (CT) in metastatic breast cancer patients (PTS) (2000) (0)
- 230P Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study (2022) (0)
- [Operable breast cancer without axillary node involvement: current therapeutic concepts]. (1989) (0)
- Methodological and reporting standards for quality of life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. (2022) (0)
- Speaker's abstract Session 1. News since St. Gallen 2001New data on chemotherapy in the adjuvant setting (2003) (0)
- Molecular alterations in breast cancers : deregulation of c-erbB2 gene expression. (1993) (0)
- 2122 POSTER Efficacy of combined Trastuzumab and CMF therapy in women with metastatic breast cancer. EORTC protocol 10995 (2007) (0)
- Do We Have Good Surrogate Endpoints for Survival in Breast Cancer Studies? (2000) (0)
- The legacy of Thomas Tursz: building a leading comprehensive cancer center in Europe. (2018) (0)
- Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score (2018) (0)
- PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. (2023) (0)
- Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer (2011) (0)
- Abstract P5-14-01: Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial (2023) (0)
- S43 EORTC and big trials (1998) (0)
- Abstract P3-01-13: Association between the histopathological growth patterns (HGP) of liver metastases (LM) and survival after hepatic surgery in patients with oligometastatic breast cancer (BC) (2020) (0)
- Innovative approaches to the treatmnet of advanced breast cancer (1997) (0)
- Abstracts of the multidisclplinary congress of the Belgian Society of Radiotherapy-Oncology, the Belgian Society of Senology and the Belgian Society of Medical Oncology (19 November 1988) (1989) (0)
- Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. (2023) (0)
- Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. (2023) (0)
- Clinical validation of in vitro drug sensitivity microarray data: Regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01) (2007) (0)
- Collaboration between large intergroups and the pharmaceutical industry (1999) (0)
- PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS (2019) (0)
- Abstract S4-02: Principles governing A-to-I RNA editing in breast cancer transcriptome (2015) (0)
- Innovative approaches to the treatment of advanced breast cancer: introduction. (1997) (0)
- HER2/neu as a predictive factor in breast cancer (1999) (0)
- Clinical Trials 102: New Strategies in Targeted Therapy Clinical Trials. (2009) (0)
- Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes (2008) (0)
- Drugs prescribed for elderly oncologic patients hospitalized in the geriatric oncology unit of Institut Jules Bordet: Polypharmacy and impact of clinical pharmacist (2012) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) (0)
- ISY3-4Metastatic breast cancer: time for action using in depth tumor molecular characterization (2015) (0)
- 218 External Barries to Effective Care in Clinical Research (2012) (0)
- Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study (2013) (0)
- Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer (1995) (0)
- 188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis (2020) (0)
- Abstract PD8-02: Phylogenetic reconstruction of advanced breast cancer reveals two different routes of metastatic dissemination associated with distinct clinical outcome (2020) (0)
- Abstract 3962: Circulating tumor DNA (ctDNA) as an alternative to tumor biopsies for precision oncology: The Jules Bordet Institute experience (2016) (0)
- Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials (2012) (0)
- PP1. Resource implications of paclitaxel/cisplatinum versus cyclophosphamide/cisplatinum in the treatment of advanced ovarian cancer. (1997) (0)
- Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial. (2018) (0)
- This is a repository copy of Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. (2018) (0)
- 215 High quality gene expression microarray data from the EORTC 10994/BIG 00-01 breast cancer study (2004) (0)
- 2161 POSTER INTEGRATE: Driving Excellence in Integrative Cancer Research Through Innovative Biomedical Infrastructures (2011) (0)
- 12 Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial (2012) (0)
- University of Birmingham Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials (2018) (0)
- Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
- The triple negative profile dilemma and its clinical outcome in early breast cancer (2006) (0)
- 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO) (2020) (0)
- Comprar Adjuvant Breast Cancer Treatment | Piccart, Martine | 9780387751146 | Springer (2008) (0)
- Clinical and pharmacoklnetic evaluation of the new blsnaphtalamlde LU 79553 administered every 21 days in patients with solid tumors: An EORTC/ECSG study (1997) (0)
- 223 A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer (2010) (0)
- Strategies therapeutiques optimales dans le cancer epithelial de l'ovaire en 1997 (1997) (0)
- Peripheral blood progenitor cell collection after docetaxel and lenograstim in patients with metastatic breast cancer (1998) (0)
- The expression of ps2 and c-myc mRNAs are powerful predictors of relapse and death in breast cancers. (1994) (0)
- 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast (2021) (0)
- Abstract P2-04-04:BRCAgene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer (2017) (0)
- A01*Genomic hallmarks of invasive lobular breast carcinoma and their clinical relevance (2015) (0)
- IS2–4ROLE OF TARGETED THERAPY IN THE TREATMENT OF PRIMARY BREAST CANCER (2013) (0)
- Optimal primary treatment of patients with an HER2 overexpressing tumour (2004) (0)
- Abstract P2-01-04: Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab (2023) (0)
- ' s response to reviews Title : The Src inhibitor dasatinib stimulates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts (2010) (0)
- ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. (2022) (0)
- S34 Dose intensity and dose density (1998) (0)
- Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial. (2018) (0)
- [Preliminary study of a combination of fluorouracil and cisplatin in the treatment of tumors of the colon]. (1983) (0)
- Abstract 3541: CD4+ T cells infiltrating human breast cancer are critical for an effective anti-tumor immune response (2012) (0)
- Oxaliplatin in patients with advanced ovarian cancer after failure of Topotecan and/or liposomal doxorubicin based chemotherapy (2003) (0)
- Abstract PD14-05: Portraying tumor evolution of lobular breast cancer through phylogenetic analysis (2022) (0)
- SoMore trial:Prospective multicentric clinical and metabolic assessment of a sorafenib(SOR)-capecitabine(CAP)combination in patients with chemorefractory advanced colorectal cancer(aCRC) (2012) (0)
- HER-2 as aT arget for Breast Cancer Therapy (2009) (0)
- Current status and future directions in the standard adjuvant therapy for operable breast cancer (1998) (0)
- 84TiP Neo-CheckRay: Radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: A randomized phase II trial (2020) (0)
- Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial (2018) (0)
- Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial (2022) (0)
- Farnesoid X receptor (FXR) status complements the evaluation of estrogen receptor alpha (ER) in breast cancer (BC) patients and predicts benefit from tamoxifen (2008) (0)
- 39OConstitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer (2015) (0)
- [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases]. (1995) (0)
- Erratum (1855) (0)
- PD03-10: Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis. (2011) (0)
- [Cancer of the breast in young women: should chemotherapy be intensified?]. (1992) (0)
- Phase I a nd P harmacokinetic S tudy o f t he O ral F arnesyl Transferase I nhibitor S CH 6 6336 G iven T wice D aily t o Patients W ith A dvanced S olid T umors (2001) (0)
- 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT (2020) (0)
- Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al. (2016) (0)
- EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration (1998) (0)
- Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
- Patients and Methods Patient Selection (2003) (0)
- 67P Digital analysis of distant and cancer-associated adipocytes in breast cancer (2020) (0)
- Abstract P4-02-04: Tumor-infiltrating lymphocytes in invasive lobular breast cancer identify a poor prognostic sub-group (2019) (0)
- SA 8.3 Emerging new treatments in HER2 positive breast cancer (2023) (0)
- Emerging Targeted Agents for HER2-Positive Breast Cancer (2013) (0)
- S02 Beyond trastuzumab: new anti-HER2 agents (2011) (0)
- What is personalised medicine ? Let us help you understand (2014) (0)
- Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. (2023) (0)
- 153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials (2020) (0)
- PO75 RETROSPECTIVE ANALYSIS OF ADVANCED LUMINAL BREAST CANCER PATIENTS TREATED WITH ENDOCRINE THERAPY (ET) ANDPALBOCICLIBWITHINACOMPASSIONATE USE PROGRAMME (2017) (0)
- Abstract 839: HER2 expression occurs early in breast cancer dissemination (2010) (0)
- 221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO (2020) (0)
- Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. (2022) (0)
- News in systemic therapy of patients with early BC (2019) (0)
- Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01) (2023) (0)
- Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer (BC) (2021) (0)
- 158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) (2017) (0)
- ICON2 TRIAL. AUTHORS' REPLY (1999) (0)
- Abstract 3891: Tackling the obstacles facing the implementation of a molecular screening program in an early drug development unit: The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions - feasibility (Precision-f) (2015) (0)
- Locally-advanced breast cancer: the EORTC-Breast cancer cooperative group experience (1997) (0)
- Abstract CS1-2: Small Tumor – Aggressive Biology: When They Collide! (2012) (0)
- 137 Optimising anti-HER2 therapy in early breast cancer (2009) (0)
- Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials (2023) (0)
- HER2+ circulating tumor cells (CTCs): a more sensitive and specific marker for CTCs positivity than total CTCs count in early breast cancer. (2009) (0)
- “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores (2022) (0)
- [The role of chemotherapy in the treatment of testicular cancer with the exception of seminomas]. (1983) (0)
- P85 Feasibility of docetaxel (D)-containing regimens in the adjuvant treatment (AT) of breast cancer (BC) (1998) (0)
- [Adjuvant treatment of breast cancer: past, present and future]. (1988) (0)
- BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole (2011) (0)
- [Therapeutic update on cancer of the breast]. (2000) (0)
- Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer (2019) (0)
- Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al. (2016) (0)
- Abstract P5-18-19: The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later (2012) (0)
- [Kidney cancer: from biology to clinical medicine]. (2006) (0)
- Abstract P3-04-10: Comparison between RNA-Seq and Affymetrix gene expression data (2012) (0)
- Breast Cancer Therapies in Development (1997) (0)
- The Legacy of Professor Aron Goldhirsch. (2020) (0)
- Taxanes: The Role in Metastatic Breast Cancer and Beyond (2003) (0)
- The Genomic Grade Index (GGI) – a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial (2008) (0)
- Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer (2020) (0)
- 2 INVITED Moving cancer treatment into the 21st century (2007) (0)
- [News in the medical treatment of breast cancer]. (2003) (0)
- EORTC 10941; Final results of a phase II study of liarozole fumarate in patients with metastatic breast cancer (1998) (0)
- Introducing Breast Cancer Research's updates on clinical trials (2004) (0)
- Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial (2013) (0)
- Circulating Tumor DNA in HER2-Ampli fi ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (0)
- Trastuzumab exerts its action HER 2-Targeted Therapy (0)
- Implementing circulating tumor cells in routine practice of breast cancer management: overview of the interventional trials (2013) (0)
- P2-18-01: The Magnitude of Trastuzumab Benefit in HER2−Positive (HER2+) Lobular Breast Carcinoma (BC): Results of a HERA Trial Sub-Group Analysis. (2011) (0)
- 439 Correlation between efficacy of single-agent Trastuzumab (T) and molecular markers in HER-2 positive advanced breast cancer patients (2003) (0)
- Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863) (2004) (0)
- Abstract 4895: Component of the gene silencing machinery: SMCX/JARID1C a new prognostic marker for breast cancer (2010) (0)
- Evaluation of HER-2 protein expression in primary breast cancer (PBC) by immunohistochemistry (IHC): An interlaboratory study assessing the reproducibility of HER-2 testing (2001) (0)
- 265PDTEN-YEAR SAFETY AND EFFICACY ANALYSES OF THE BIG 02-98 PHASE III TRIAL WITH AN EXPLORATORY ANALYSIS ON THE ROLE OF KI67 IN PREDICTING BENEFIT OF ADJUVANT DOCETAXEL IN ER POSITIVE PATIENTS. (2014) (0)
- Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. (2023) (0)
- A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours (2006) (0)
- [Systemic adjuvant therapy of breast cancer: myths and controversies]. (1996) (0)
- Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007) (2012) (0)
- Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2018) (0)
- Could the D5 antigen replace estrogen and progesterone receptors (ER & PGR) as a marker of hormone dependency and a prognostic factor in early breast cancer (BC)? (1990) (0)
- The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later (2012) (0)
- Abstract 3698: Unraveling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis (2018) (0)
- Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial (2017) (0)
- Abstracts reprinted from Journal of Clinical Oncology (2007) (0)
- Tracking Tobacco Use for Trials and Treatment (2013) (0)
- How do cancer centres communicate clinical trials opportunities to patients on their websites (2017) (0)
- Docetaxel (D) in combination with amifostine (A) in metastatic breast cancer (MBC): A feasibility and pharmacoklnetlc study of the EORTC-investigational drug branch for breast cancer (IDBBC) (1997) (0)
- Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Martine J. Piccart?
Martine J. Piccart is affiliated with the following schools:
- Karolinska Institute
- Leiden University
- Medical University of Vienna
- Institute of Cancer Research
- Paris Sciences et Lettres University
- University of Oxford
- KU Leuven
- McMaster University
- University of Toronto
- University of Turin
- Université libre de Bruxelles
- University of Antwerp
- University of Milan
- University of British Columbia
- University of Edinburgh
